An inherited NBN mutation is associated with poor prognosis prostate cancer

British Journal of Cancer

Volumn 108, Issue 2, 2013, Pages 461-468

  Cybulski, C ^a   Wokolorczyk D ^a   Kluzniak W ^a   Jakubowska, A ^a   Gorski B ^a   Gronwald, J ^a   Huzarski, T ^a   Kashyap, A ^a   Byrski, T ^a   Debniak T ^a   Golab A ^a   Gliniewicz, B ^a,b   Sikorski, A ^a   Switala J ^b   Borkowski, T ^c   Borkowski, A ^c   Antczak, A ^d   Wojnar, ^d   Przybyla J ^e   Sosnowski, M ^e   Malkiewicz B ^f   Zdrojowy, R ^f   Sikorska Radek, P ^g   Slojewski M ^a   Matych, J ^g   Wilkosz, J ^e   Rozanski W ^e   Kis J ^h   Bar, K ^h   Bryniarski, P ⁱ   Paradysz, A ⁱ   Jersak, K ^j   Niemirowicz, J ^j   Slupski P ^k   Jarzemski, P ^k   Skrzypczyk, M ^l   Dobruch, J ^l   Domagala P ^a   Narod, S A ^m   Lubinski J ^a   Masojc B ^a   Van De Wetering, T ^a   Serrano Fernandez P ^a   Puszynski M ^a   Soczawa, M ^a   Archimowicz, S ^b   Kordowski, M ^b   Zlyczkowski M ⁱ   Domagala W ^j   Chosia, M ^j   Borowka A ^m   Baginska J ⁿ   Krajka, K ⁿ   Szwiec, M ^o   Stawicka, M ^p   Haus, O ^q   Janiszewska, H ^q   Stembalska, A ^f   Sasiadek M M ^f   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Maria Sk odowska Curie Hospital   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g Regional Hospital   (Poland)

^h University of Lublin   (Poland)

ⁱ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^j Ministry of Internal Affairs and Administration Hospital   (Poland)

^k Wojewodzki Szpital im Dr J Biziela w Bydgoszczy   (Poland)

^l Department of Urology   (Poland)

^m Centre for Research on Women's Health   (Canada)

ⁿ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^o Regional Oncology Hospital   (Poland)

^p NZOZ Center for Medical Genetics   (Poland)

^q NICOLAUS COPERNICUS UNIVERSITY   (Poland)

more..

Author keywords

Aggressive prostate cancer; BRCA1; CHEK2; NBN; NBS1; Survival

Indexed keywords

BRCA1 PROTEIN; CHECKPOINT KINASE 2; NIBRIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FAMILIAL CANCER; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLAND; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; CELL CYCLE PROTEINS; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84873717865     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.486     Document Type: Article

References (45)

1. Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chow WH, Rothman N, Chabrier A, GaborieaüV, Odefrey F, Southey M, Hashibe M, Hall J, Boffetta P, Peto J, Peto R, Hung RJ (2007) Uncommon CHEK2 missense variant and reduced risk of tobacco-related cancers: Case control study. Hum Mol Genet 16: 1794-1801. (Pubitemid 47244527)
2. Chrzanowska KH, Piekutowska-Abramczuk D, Popowska E, G"adkowska-Dura M, Ma"dyk J, Syczewska M, Krajewska-Walasek M, Goryluk-Kozakiewicz B, Buba"a H, Gadomski A, Gaworczyk A, Kazanowska B, Ko"tan A, Kuźmicz M, Luszawska-Kutrzeba T, Maciejka-Kapuścińska L, Stolarska M, Stefańska K, Sznurkowska K, Wakulińska A, Wieczorek M, Szczepański T, Kowalczyk J (2006) Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies. Int J Cancer 118: 1269-1274. (Pubitemid 43185616)
3. Cybulski C, Górski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojć B, Jakubowska A, Matyjasik J, Z"owocka E, Sikorski A, Narod SA, Lubiński J (2004) NBS1 is a prostate cancer susceptibility gene. Cancer Res 64: 1215-1219. (Pubitemid 38235583)
4. Cybulski C, Woko"orczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Ma"kiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubiński J (2006) A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 43: 863-866. (Pubitemid 44787112)
5. Cybulski C, Woko"orczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojć B, Debniak T, Górski B, Blecharz P, Narod SA, Lubiński J (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29: 3747-3752.
6. Digweed M (1993) Human genetic instability syndromes: Single gene defects with increased risk of cancer. Toxicol Lett 67: 259-281.
7. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P (2010) Screening for prostate cancer: Systematic review and metaanalysis of randomised controlled trials. BMJ 341: 4543-4543.
8. Djulbegovic M, Neuberger MM, Dahm P (2012) Prostate-cancer mortality after PSA screening. N Engl J Med 366: 2228-2229.
9. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, ThibodeaüSN, LiüW (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72: 270-280. (Pubitemid 36194238)
10. Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA. UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology (2010) Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 103: 918-924.
11. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA. Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72: 1-12. (Pubitemid 36056838)
12. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, XüJ, Carpten JD, Isaacs WB, Cooney KA (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366: 141-149.
13. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343: 692-695. (Pubitemid 24087847)
14. Futaki M, Lui JM (2001) Chromosome breakage syndromes and the BRCA1 genome surveillance complex. Trends Mol Med 7: 560-565. (Pubitemid 33127142)
15. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G, Easton D, Clayton D, Stratton MR, Ponder BA (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11: 428-433.
16. Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, Greene MH, Maslansky B, Fischbein A, Gruber SB, Rennert G, Ronchetti RD, Hewitt SM, Struewing JP, Iscovich J (2003) A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40: 787-792. (Pubitemid 37311080)
17. Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbański K, Mituś J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Debniak T, To"oczko-Grabarek A, Medrek K, Masojć B, Mierzejewski M, Kowalska E, Narod SA, Lubiński J (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92: 19-24. (Pubitemid 40875074)
18. Gronwald J, Huzarski T, Byrski B, Medrek K, Menkiszak J, Monteiro AN, Sun P, Lubinski J, Narod SA (2006) Cancer risks in first degree relatives of BRCA1 mutation carriers: Effects of mutation and proband disease status. J Med Genet 43: 424-428.
19. Hebbring SJ, Fredriksson H, White KA, Maier C, Ewing C, McDonnell SK, Jacobsen SJ, Cerhan J, Schaid DJ, Ikonen T, Autio V, Tammela TL, Herkommer K, Paiss T, Vogel W, Gielzak M, Sauvageot J, Schleutker J, Cooney KA, Isaacs W, ThibodeaüSN (2006) Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 15: 935-938. (Pubitemid 43823520)
20. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA (1996) Growth retardation and tumour inhibition by BRCA1. Nat Genet 12: 298-302. (Pubitemid 26080089)
21. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297: 606-609. (Pubitemid 34815345)
22. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10: 2918-2921. (Pubitemid 38619665)
23. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D, UKGPCS Collaborators, Goldgar D, Eeles R (2011) BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer 105: 1230-1234.
24. Lee JH, Paull TT (2004) Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science (New York, NY) 304: 93-96. (Pubitemid 38451463)
25. Lee JH, Paull TT (2005) ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science (New York, NY) 308: 551-554. (Pubitemid 40570585)
26. Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D, UKGPCS Collaborators, Goldgar D, Eeles R, Kote-Jarai Z (2012) Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 106: 1697-1701.
27. Maser RS, Zinkel R, Petrini JH (2001) An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. Nat Genet 27: 417-421. (Pubitemid 32268423)
28. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y, Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, KyriacoüK, van Asperen C, Kiemeney L, IMPACT Study Collaborators, Easton DF, Eeles RA (2011) Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJÜInt 107: 28-39.
29. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, Ghadirian P, Cummings S, Olopade O, Stoppa-Lyonnet D, Couch F, Wagner T, Warner E, Foulkes WD, Saal H, Weitzel J, Tulman A, Poll A, Nam R, Sun P, Hereditary Breast Cancer Study Group, Danquah J, Domchek S, Tung N, Ainsworth P, Horsman D, Kim-Sing C, Maugard C, Eisen A, Daly M, McKinnon W, Wood M, Isaacs C, Gilchrist D, Karlan B, NedelcüR, Meschino W, Garber J, Pasini B, Manoukian S, Bellati C (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99: 371-374.
30. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King MC, Goldgar DE (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study. Am J Hum Genet 58: 271-280. (Pubitemid 26038932)
31. Petrini JH (1999) The mammalian Mre11-Rad50-nbs1 protein complex: Integration of functions in the cellular DNA-damage response. Am J Hum Genet 64: 1264-1269. (Pubitemid 30468742)
32. Rennert G, Dishon S, Rennert HS, Fares F (2005) Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel. Eur J Cancer Prev 14: 357-361. (Pubitemid 41104944)
33. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A. ERSPC Investigators (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: 981-990.
34. Seppa?la? EH, Ikonen T, Mononen N, Autio V, Rökman A, Matikainen MP, Tammela TL, Schleutker J (2003) CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 89: 1966-1970. (Pubitemid 37533278)
35. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjörd JE, Jonsson E (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75: 758-761. (Pubitemid 27451978)
36. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408. (Pubitemid 27208598)
37. Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002a) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365. (Pubitemid 35154140)
38. Thompson D, Easton D, Breast Cancer Linkage Consortium (2002b) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11: 329-336. (Pubitemid 34408211)
39. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjörd JE (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60: 1079-1084. (Pubitemid 27194092)
40. Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S, Hopper JL, Kathleen Cunningham Consortium for Research in Familial Breast Cancer Consortium, Bolton D (2011) Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 4: 1002-1010.
41. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91: 1241-1247. (Pubitemid 29357191)
42. Willems AJ, Dawson SJ, Samaratunga H, De Luca A, Antill YC, Hopper JL, Thorne HJ. kConFab Investigators (2008) Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clin Cancer Res 14: 2953-2961.
43. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, Beckmann G, Seemanová E, Cooper PR, Nowak NJ, Stumm M, Weemaes CM, Gatti RA, Wilson RK, Digweed M, Rosenthal A, Sperling K, Concannon P, Reis A (1998) Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93: 467-476. (Pubitemid 28232090)
44. Varon R, Seemanova E, Chrzanowska K, Hnateyko O, Piekutowska-Abramczuk D, Krajewska-Walasek M, Sykut-Cegielska J, Sperling K, Reis A (2000) Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 8: 900-902.
45. Zuhlke KA, Johnson AM, Okoth LA, Stoffel EM, Robbins CM, Tembe WA, Salinas CA, Zheng SL, XüJ, Carpten JD, Lange EM, Isaacs WB, Cooney KA (2012) Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. Fam Cancer; e-pub ahead of print 5 August 2012.